Literature DB >> 2042391

Efficacy studies on a canarypox-rabies recombinant virus.

J Taylor1, C Trimarchi, R Weinberg, B Languet, F Guillemin, P Desmettre, E Paoletti.   

Abstract

Recombinant avipox viruses have been developed expressing the rabies glycoprotein gene. A fowlpox-rabies recombinant has previously been shown to be protective against live rabies virus challenge in a number of non-avian species. This report describes the development of a canarypox-rabies recombinant. A comparison is made of the protective efficacy of this recombinant with other pox-rabies recombinants.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2042391     DOI： 10.1016/0264-410x(91)90152-v

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  29 in total

1.  Approaches for genetic purity testing of live recombinant viral vaccines using a human adenovirus:rabies model.

Authors:  C Lutze-Wallace; T Sapp; S A Nadin-Davis; A Wandeler
Journal:  Can J Vet Res       Date:  1992-10       Impact factor: 1.310

2.  Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine.

Authors:  Reuben K Soi; Fred R Rurangirwa; Travis C McGuire; Paul M Rwambo; James C DeMartini; Timothy B Crawford
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

3.  In vitro assessments of the genetic stability of a live recombinant human adenovirus vaccine against rabies.

Authors:  C Lutze-Wallace; T Sapp; M Sidhu; A Wandeler
Journal:  Can J Vet Res       Date:  1995-04       Impact factor: 1.310

Review 4.  Progress and challenges toward an AIDS vaccine: Brother, can you spare a paradigm?

Authors:  W C Koff; A M Schultz
Journal:  J Clin Immunol       Date:  1996-05       Impact factor: 8.317

Review 5.  Non-replicating expression vectors: applications in vaccine development and gene therapy.

Authors:  K J Limbach; E Paoletti
Journal:  Epidemiol Infect       Date:  1996-06       Impact factor: 2.451

Review 6.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

Review 7.  Applications of pox virus vectors to vaccination: an update.

Authors:  E Paoletti
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

8.  Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light.

Authors:  K Tsung; J H Yim; W Marti; R M Buller; J A Norton
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

Review 9.  Reflections on the early development of poxvirus vectors.

Authors:  Bernard Moss
Journal:  Vaccine       Date:  2013-04-10       Impact factor: 3.641

10.  The genome of canarypox virus.

Authors:  E R Tulman; C L Afonso; Z Lu; L Zsak; G F Kutish; D L Rock
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.